(Q37177600)

18 August 2017

1 reference

title

EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future (English)

1 reference

non-small-cell lung carcinoma

18 August 2017

1 reference

Chih-Hsin Yang

1

1 reference

18 August 2017

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

60 Suppl 2

1 reference

18 August 2017

S23-30

1 reference

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Predictors of the response to gefitinib in refractory non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

EGFR mutation and response of lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

EGFR exon 20 insertion mutation in Japanese lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

EGFR and erbB2 mutation status in Japanese lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

K-ras gene mutation in sputum samples containing atypical cells and adenocarcinoma cells in the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970102-8

7 January 2021

10.1016/S0169-5002(08)70102-8

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18513581